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Objective

 Is there an ethnic disparity regarding the effect of

plasma albuterol on:
 Potassium
 Magnesium
 Bicarbonate
 Phosphate
 Glucose

β2-Agonists and Electrolyte
Abnormalities

 Potassium
 Hypokalemia through increased cellular uptake
 Glucose
 Gluconeogenesis
 Phosphate
 Hypophosphatemia may be associated with

ventilatory failure
 Bicarbonate
 Increase in lactic acidosis (Type B) in asthma

Ethnic Differences in Asthma
 Higher morbidity and mortality in African Americans

compared to Caucasians with asthma
 Higher rates of ED visits (350%) and hospitalizations

(240%)
 Reports of interethnic differences in β2 treatment for

acute asthma
 SABA overuse and tolerance mechanism
 Genetic differences at β2-receptor

Study Methods
MN-221 Trial
 Sub-group analysis of

large, multi-center RCT
evaluating a novel IV β2agonist for acute asthma
exacerbation

Select Exclusion Criteria
 <18 and >55 years old
 At risk for increased β1 response
 Significant smoking history
 COPD, or other chronic lung

disease or respiratory dysfunction

Methods Continued
Subject Inclusion
 Serum Mg, K, bicarbonate, and

glucose were measured at
“baseline” and “1.25hrs postbaseline”
 70 placebo subjects with plasma

albuterol (R- and S-) data

Analysis
 Percent of lab values outside

normal range
 Pearson correlations for

albuterol to
electrolyte/glucose
concentration

Results

 43 African-Americans and 27 Caucasians
 Significant correlations observed in 4/5 measures, all ethnic specific
 Largest effect size with potassium and bicarbonate
 Smaller effect size with magnesium and glucose
 No effect with Phosphate, however large % low values

Correlation Results
Pearson r [95% CI]
p value, R2
Magnesium (mEq/L)
Potassium (mmol/L)
Glucose (mg/dL)
Phosphate (mg/dL)
Bicarbonate (mmol/L

Total albuterol:
Caucasians

Total albuterol:
African-Americans

-0.15 [-0.43, -0.15]

0.36 [0.13, 0.56]

p= 0.32

p<0.01*, 0.13

-0.55 [-0.7, -0.31]

-0.08 [-0.31, -0.14]

p< 0.01*, 0.31

p=0.44

0.34 [0.07, 0.56]

0.10 [-0.11, 0.32]

p=0.015*, 0.11

p=0.33

-0.07 [-0.35, 0.21]

0.15 [-0.07, 0.36]

p= 0.62

p= 0.17

-0.55 [-0.72, -0.32]

-0.15 [-0.35, 0.07]

p<0.01*, 0.30

p= 0.18

Metabolic Abnormalities
Value
[Lab Cut-Off]

Median [IQR]

N (%) AA ONR

N (%) CA ONR

Potassium
[<3.6] mmol/L

3.8 [3.5-4.1]

14 (32.5%)

11 (46%)

Magnesium
[>2.1] mEq/L

1.7 [1.5-1.8]

3 (8.8%)

0 (0%)

Phosphate
[<2.4] mg/dL

2.7 [2.3-3.2]

17 (40.5%)

10 (40%)

Bicarbonate
[<20] mEq/L

22 [20-24]

10 (23%)

9 (36%)

Glucose
[>140] mg/dL

120 [107-152]

22 (51%)

11 (42%)

Conclusions
 Ethnic-specific correlations between plasma albuterol and

serum K, Bicarb, Mg, and Glu.
 Specific to Caucasian population:
 Sig negative correlation with K and Bicarb
 Sig positive correlation with Glucose
 Specific to African American population:
 Sig positive correlation with Mg
 High % hypophosphatemia observed for both populations

Potential Clinical Implications

 When repeated β2-agonist treatments given for acute asthma,

closer ED monitoring may be required for:
 Low K, low Bicarb and high Glucose in Caucasians
 High magnesium in African Americans
 Future research implications
 These data suggest that combining ethnic groups may mask

true effect size in one group

Limitations

 Clinical relevance depends on magnitude of change—

generally small effect size observed
 Relatively small sample size due to sub-group analysis

Questions?
Questions?

Exclusion Criteria
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•

Administration of parenteral (intravenous or subcutaneous) beta agonist within 6 hours prior to
randomization.
A current or prior diagnosis or suspected diagnosis of COPD or other chronic lung disease other
than asthma, the presence of pneumonia, or presence of significant other respiratory dysfunction
such as pneumothorax, pneumomediastinum, or pulmonary edema.
Known or suspected vocal cord dysfunction syndrome or the presence of aspirated foreign body
(known or suspected).
History of any current clinical evidence suggesting cardiomyopathy or congestive heart failure,
history or presence of tachyarrhythmia, with the exception of sinus tachycardia, or a heart rate ≥ 140
bpm.
Hypokalemia, defined as potassium level ≤ 2.8 mEq/L obtained at Screening.
Significant cardiac, renal, hepatic, endocrine, metabolic, neurologic or other systemic disease.
Self-reported history of greater than 15 packer year smoking history.
Fever ≥ 102.0 ˚F (38.9˚C).
Uncontrolled hypertension defined as blood pressure ≥ 170/100 mm Hg.
Need for immediate intubation, mechanical ventilation, or non-invasive positive pressure ventilation
as determined by the Investigator.
Pregnant or lactating females.
Participating in another clinical study with an investigational drug within 30 days of randomization.
Positive urine drug screen for cocaine, methamphetamine or PCP.
Any subject with a known allergy components of the MN-221 drug product or other beta agonists.
Previous exposure to MN-221
Use of theophylline, beta blockers, diuretics, digoxin, MAO inhibitors, or tricyclic antidepressants,
within 2 weeks prior to randomization.

Exclusion Criteria

Plasma/ Nebulized
Albuterol Correlation

Dose
Plasma/NebulizedNebulized
Albuterol

Plasma Albuterol Mean
Total (R+S)

7.0 ng/mL

(mg)
12.1 mg

